Why the study?
Does tanshinone IIA pretreatment improve cardiac function and reduce myocardial apoptosis in experimental diabetic cardiomyopathy?
Does tanshinone IIA pretreatment improve cardiac function and reduce myocardial apoptosis in experimental diabetic cardiomyopathy?
Tanshinone IIA exerts cardioprotective effects in experimental diabetic cardiomyopathy via the kinin B2 receptor-Akt-GSK-3β dependent pathway.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for tanshinone IIA in diabetic cardiomyopathy; prospective human trials needed before clinical consideration.
AIMS: Diabetic cardiomyopathy, characterized by myocardial structural and functional changes, is a specific cardiomyopathy develops in patients with diabetes mellitus. The present study was to investigate the role of kinin B2 receptor-Akt-glycogen synthase kinase (GSK)-3β signalling pathway in mediating the protective effects of tanshinone IIA (TSN) on diabetic cardiomyopathy. METHODS AND RESULTS: Streptozocin (STZ) induced diabetic rats (n = 60) were randomized to receive TSN, TSN plus HOE140 (a kinin B2 receptor antagonist), or saline. Healthy Sprague-Dawley (SD) rats (n = 20) were used as control. Left ventricular function, myocardial apoptosis, myocardial ultrastructure, Akt, GSK-3β and NF-κB phosphorylation, the expression of TNF-α, IL-6 and myeloperoxidase (MPO) were examined. Cardiac function was well preserved as evidenced by increased left ventricular ejection fraction (LVEF) and ± dp/dt (maximum speed of contraction/relaxation), along with decreased myocardial apoptotic death after TSN administration. TSN pretreatment alleviated mitochondria ultrastructure changes. TSN also enhanced Akt and GSK-3β phosphorylation and inhibited NF-κB phosphorylation, resulting in decreased TNF-α, IL-6 and MPO activities. Moreover, pretreatment with HOE140 abolished the beneficial effects of TSN: a decrease in LVEF and ± dp/dt, an inhibition of cardiomyocyte apoptosis, a destruction of cardiomyocyte mitochondria cristae, a reduction of Akt and GSK-3β phosphorylation, an enhancement of NF-κB phosphorylation and an increase of TNF-α, IL-6 and MPO production. CONCLUSION: These data indicated that TSN is cardioprotective in the context of diabetic cardiomyopathy through kinin B2 receptor-Akt-GSK-3β dependent pathway.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: